^
Association details:
| Biomarker: | DLL3 underexpression |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | tarlatamab (AMG 757) (CD3 agonist, DLL3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer
Published date:
11/17/2020
Excerpt:
AMG 757 showed potent and specific killing of even those SCLC cell lines with very low DLL3 expression (<1,000 molecules per cell).
DOI:
10.1158/1078-0432.CCR-20-2845
